Abcam, ab284052, Anti-SARS-CoV-2 nsp16 antibody [EPR24841-18] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal R1AB antibody. Carrier free. Suitable for Flow Cyt (Intra), ICC/IF, WB, I-ELISA and reacts with Transfected cell line - SARS-CoV-2, Recombinant full length protein - SARS-CoV-2 samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24841-18,
Isotype:IgG,
Carrier free:Yes,
Reacts with:SARS-CoV-2,
Applications:I-ELISA, ICC/IF, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab284052 is the carrier-free version of
ab284038
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SARS-CoV-2 nsp16 also known as non-structural protein 16 is an important enzyme in the replication and transcription machinery of the virus. It exhibits 2'-O-methyltransferase activity and has a molecular mass of approximately 33 kDa. Nsp16 is expressed in host cells once the virus infects the cell and translates its polyproteins. Its main role is to modify the cap structure of viral mRNA which helps in avoiding host immune detection and promoting efficient viral replication.
Biological function summary
The function of nsp16 centers around its interaction with nsp10 forming a stable 2'-O-methyltransferase complex. This enzyme complex is responsible for the methylation of the ribonucleic acid cap at the first nucleotide. This cap modification is necessary for the stability of the viral mRNA and its ability to be recognized by the host's cellular machinery as native mRNA which prevents antiviral defenses from targeting the virus. The methylation activity of nsp16 is highly specific requiring both nsp10 and nsp16 to function together effectively.
Pathways
Nsp16 plays an integral role in the viral replication-transcription complex (RTC) pathway. This pathway is essential for the synthesis of viral genomic and subgenomic RNAs facilitating the life cycle of SARS-CoV-2. The RTC includes other viral proteins like nsp12 which acts as the RNA-dependent RNA polymerase. These interactions ensure the replication fidelity and quantity necessary for viral protein production and spreading within the host organism.
Nsp16 is connected to COVID-19 the disease caused by SARS-CoV-2 infection. Its role in immune evasion makes it a target for antiviral drug development as disabling the nsp16 function could make the virus more susceptible to host immune responses. nsp16's cooperation with nsp10 is also significant in this context as disrupting their interaction might prevent the virus from effectively replicating offering a potential therapeutic strategy to combat COVID-19.